H. Lundbeck A/s Class A · OMXCOP:HLUN_A
H. Lundbeck A/s Class A — Shareholder Meeting (March 2025)
45 slides from H. Lundbeck A/s Class A's shareholder meeting presentation, Mar 26, 2025
Slide 1: H. Lundbeck A/S Annual General Meeting
H. Lundbeck A/S Annual General Meeting 26 March 2025 Gao Lei Living with migraine
Slide 2: Safe Harbor/Forward-Looking Statements
Safe Harbor/Forward-Looking Statements Safe Harbor/Forward-Looking Statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements i
Slide 3: Welcome
Welcome Lars Rasmussen Chair of the Board of Directors 3
Slide 4: The Board expects to elect Dorothea Wenzel as Chair of the Board
The Board of Directors expects to elect Dorothea Wenzel as Chair of the Board • Member of the H. Lundbeck A/S Board of Directors since 2021 (Chair of Audit Committee) • PhD in Health Economics & Macroeconomics and a M.Sc. in Business & Computer Sciences from the University of Darmstadt in Germany. V
Slide 5: Board of Directors 2024
Board of Directors 2024 Lars Søren Rasmussen Lene Skole-Sørensen Santiago Arroyo Jeffrey Berkowitz Dorothea Wenzel Chair Deputy Chair Jakob Riis Lars Erik Holmqvist Dorte Clausen Lasse Skibsbye Camilla Gram Hossein Armandi Andersson Elected by the employees for the period 2022-2026 5
Slide 6: Our Executive Management Team
Our Executive Management Team Charl van Zyl Maria Alfaiate Lars Bang Michala Fischer-Hansen President and CEO Executive Vice President, Executive Vice President, Executive Vice President, Commercial & Corporate Product Development & Europe & International Strategy Supply Operations Thomas Gibbs Dian
Slide 7: Annual General Meeting
Annual General Meeting Jørgen Kjergaard Madsen
Slide 8: Agenda
Agenda In accordance with Article 8.1 of the Articles of Association 01 Report from the Board of Directors 07 Election of state authorized public accountants 02 Approval of the Annual Report 08 Proposals from shareholders or the 03 Resolution on the appropriation of Board of Directors: profit or los
Slide 9: 01: Report from the Board of Directors
01: Report from the Board of Directors Lars Rasmussen
Slide 10: We reached 7.2 million patients on a daily average
We reached 7.2 million patients on a daily average. People with brain diseases are always at the center of what we do 10
Slide 11: Leveraging our neuroscience knowledge and competencies
Leveraging our neuroscience knowledge and competencies Our three selected strategic focus areas Grow our Expand on Build psychiatry neuro-speciality neuro-rare core position franchise 11
Slide 12: 2024 is a transformative year for Lundbeck
2024 is a transformative year for Lundbeck Focused innovation Record revenue (+14% growth) Secure mid-term Aiming for - Strategic brands +21% growth growth 4 - Adjusted EBITDA +20% growth assets in Phase III in 2026 Advancing and broadening innovative pipeline Lead with focused innovation - Acquirin
Slide 13: Lundbeck's B-share has increased +21% since January 2024
Lundbeck’s B-share has increased +21% since January 2024 Traded volume Index Brexpipraz Longboard (million shares) ole PTSD acquisition CME 2024 submitted Q2 2024 + (Valby) upgrade Q1 2024 MASCOT AMULET FY 2023 initiated trial HLR PROCEED +21% initiated +20% -1% Share price: Share price: DKK 41.32 D
Slide 14: Strong revenue and profit growth
Strong revenue and profit growth Key figures DKKm Change Change FY 2024 FY 2023 (CER)1 (DKK) Revenue 22,004 19,912 14% 11% Gross margin 80.8% 77.5% +3.2pp Adjusted gross margin 88.4% 88.3% Sales and distribution (S&D) 8,146 7,482 10% 9% Administrative expenses 1,437 1,293 11% 11% Research and develo
Slide 15: Significant growth in net profit
Significant growth in net profit Net profit & adjusted net profit DKKm +26% DKK 5.261m DKK 4.192m +37% DKK 3.143m DKK 2.290m Net profit Adjusted net profit 2023 2024 15
Slide 16: Dividend payout increased by 36% versus last year
Dividend payout increased by 36% versus last year Dividend per share DKK Dividend payout +36% DKKm 1,0 DKK 0.95 2024 2023 Share Net profit for the year 3,143 2,290 DKK 0.70 DKK 0.58 Proposed dividends for the year 946 697 30% 2,197 0,5 Carried forward as retained earnings 1,593 70% Proposed dividend
Slide 17: Financial guidance for 2025
Financial guidance for 2025 Revenue growth Adjusted EBITDA growth CER CER 7% 10% 5% 11% Fuelling additional investments in Underlines ability to sustain our pipeline for future long-term profitability while expanding and growth progressing the pipeline CER: Constant Exchange Rates 17
Slide 18: Our sustainability key figures
Our sustainability key figures Business ethics compliance Climate action Chemical recycling 100% 38% 18% 62% Share of employees who completed the annual Reduction in scope 1 & Increase in scope 3 Recovery of selected organic solvents used in e-learning on our Code of Conduct, compared 2 greenhouse g
Slide 19: Update from the CEO
Update from the CEO Charl van Zyl Chair of the Board of Directors 19
Slide 20: Our people are Lundbeck's most important assets
Our people are Lundbeck’s most important assets Best Place to Work awards received in more than 12 markets 20
Slide 21: Delivering on our Focused Innovator strategy
Delivering on our Focused Innovator strategy Building our pipeline for sustainable long-term growth Strong operational momentum Targeted commercial focus Strategic brands +21% Successful launch of Rexulti AADAD in the U.S. Growth Exceptional Vyepti growth in key markets Scaling our neuro-specialty p
Slide 22: Transformed pipeline accelerating long-term growth
Transformed pipeline accelerating long-term growth Maintain momentum to enable a sustainable pipeline Phase I Phase II Phase III 2020 onwards 2023-2024 2026 Rebuilding momentum Two first-in-class Aiming through innovative early development programs … +2 proof-of-concepts achieved +4 for four assets
Slide 23: Strengthening Lundbeck's leadership in neuroscience
Strengthening Lundbeck’s leadership in neuroscience A significant step forward in Focused Innovator strategy Bexicaserin Expected launch in the • Targeting severe and rare epilepsies (Phase III) fourth quarter of 2028. • A compound with a compelling efficacy and safety + profile addressing considera
Slide 24: Advancing the robust, focused and de-risked pipeline
Advancing the robust, focused and de-risked pipeline Key events in pipeline progression Project Area Milestones Phase II OLE1 Bexicaserin (5-HT2C agonist) DEEs Read-out 12m Q1 2025 sNDA Brexpiprazole PTSD FDA Advisory Committee H1 2025 Phase Ib CAH Lu AG13909 (anti-ACTH mAb) Neuro-hormonal dysfuncti
Slide 25: Focused Innovator strategy
Focused Innovator strategy Advancing brain health and transforming lives 2024 – 2026 2027 – 2029 2030 – 2033 Focus Scale Accelerate Unmet • Grow strategic brands • Build franchise in migraine • Pipeline delivering Secure needs • Disciplined capital and neuro-rare breakthrough products mid-term growt
Slide 26: 02: Approval of the Annual Report
02: Approval of the Annual Report
Slide 27: 03: Resolution on the appropriation of profit or loss
03: Resolution on the appropriation of profit or loss
Slide 28: 03: Resolution on distribution of profit or loss
03: Resolution on distribution of profit or loss Dividend payout DKKm 2024 Share Net profit for the year 3,143 Proposed dividends for the year 946 30% Carried forward as retained earnings 2,197 70% Proposed dividend per share (DKK) 0.95 28
Slide 29: 04: Presentation of and advisory vote on the Remuneration Report
04: Presentation of and advisory vote on the Remuneration Report
Slide 30: 04: Presentation of and advisory vote on the Remuneration Report
04: Presentation of and advisory vote on the Remuneration Report The Board of Directors recommends the report to be approved. 30
Slide 31: 05: Election of members to the Board of Directors
05: Election of members to the Board of Directors
Slide 32: 05: Members of the Board of Directors elected at the 2024 AGM
05: Members of the Board of Directors - elected at the 2024 Annual General Meeting Remuneration & Nomination Audit Scientific Members Independent Committee Committee Committee 1. Lars Søren Rasmussen, Chair Yes Chair 2. Lene Skole-Sørensen, Deputy Chair No 3. Santiago Arroyo Yes Chair 4. Jeffrey Ber
Slide 33: 05: Election of members to the Board of Directors 2025
05: Election of members to the Board of Directors 2025 Proposal to strengthen the Board of Directors with a new member • Professional Board member with more than 30 years of experience from global pharmaceutical and life science industries • Most recently as CFO of Novozymes (2019-2023), where he st
Slide 34: 05: Election of members to the Board of Directors 2025
05: Election of members to the Board of Directors 2025 Dorothea Wenzel Lene Skole-Sørensen Santiago Arroyo Jeffrey Berkowitz Lars Green Lars Erik Holmqvist Jakob Riis 34
Slide 35: 06: Approval of remuneration for the Board of Directors
06: Approval of remuneration for the Board of Directors for the current financial year
Slide 36: 06: Approval of remuneration for the Board of Directors
06: Approval of remuneration for the Board of Directors for the current financial year Board of Directors DKK Current Proposal from 2025 Members of the Board 400,000 450,000 Supplement to members of the Board with permanent 400,000 400,000 residence outside of Europe Deputy Chair 800,000 900,000 Cha
Slide 37: 07: Election of state authorized public accountants
07: Election of state authorized public accountants
Slide 38: 07: Election of state authorized public accountants
07: Election of state authorized public accountants In accordance with the recommendation submitted to the Board of Directors by the Audit Committee, the Board of Directors proposes that PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab should be re-elected as auditor for the Company (
Slide 39: 08: Proposals from shareholders or the Board
08: Proposals from shareholders or the Board of Directors
Slide 40: 08: Proposal by the Board of Directors
08: Proposal by the Board of Directors 8.1. Proposal from the Board of Directors to authorize the Board of Directors to allow the Company to acquire treasury shares. The Board of Directors proposes to authorize the Board of Directors until the next annual general meeting to allow the Company to acqu
Slide 41: 08: Proposal by the Board of Directors
08: Proposal by the Board of Directors 8.2. Proposal from the Board of Directors to amend Article 7.1 of the Articles of Association as a consequence of the upcoming merger of the Capital Region of Denmark and Region Zealand. The Board of Directors proposes that the first sentence of Article 7.1 of
Slide 42: 08: Proposal by the Board of Directors
08: Proposal by the Board of Directors 8.3. Proposal from the Board of Directors to adopt the amended Remuneration Policy for the Board of Directors and Executive Management in its full wording. The amendments include a 50 % increase of the maximum payout potential under the Management’s LTI program
Slide 43: 08: Proposal by the Board of Directors
08: Proposal by the Board of Directors 8.4. Proposal from the Board of Directors to authorize the Chair of the meeting to file the resolutions passed at the annual general meeting for registration with the Danish Business Authority. The Board of Directors proposes to authorize the Chair of the Annua
Slide 44: 09: Any other business
09: Any other business
Slide 45: Thank you and goodbye
Thank you and goodbye Martha Living with depression and ADHD